Company Profile
Puma Biotechnology Inc Stock Price, News & Catalysts
- Ticker:
- PBYI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
9.84 USD (-0.91%)
Close
Last updated: October 1, 2026
355M USD
Market cap
Why the stock is moving
As of Oct 1, 2026, PBYI closed down 0.91% at $9.84. No new same-company headline was identified in the current news window.
Company overview
Commercial Oncology Company
Puma Biotechnology develops and commercializes therapies for breast cancer and other solid tumors. Its business combines the established NERLYNX franchise with clinical development of the Aurora kinase A inhibitor alisertib.
NERLYNX in HER2-Positive Breast Cancer
NERLYNX, or neratinib, is an oral irreversible pan-HER kinase inhibitor. It is approved as extended adjuvant treatment after trastuzumab-based therapy in early-stage HER2-positive breast cancer and with capecitabine in previously treated advanced or metastatic HER2-positive disease.
U.S. Commercial and International Royalty Model
Puma directly markets NERLYNX in the United States and supports access through its Patient Lynx program. International partners commercialize neratinib in other territories, providing Puma with royalty and licensing revenue.
Alisertib Development Program
Alisertib is an oral, selective inhibitor of Aurora kinase A, a protein involved in mitotic progression. Puma licensed global development and commercialization rights and is initially focusing the program on small cell lung cancer and hormone receptor-positive, HER2-negative metastatic breast cancer.
ALISCA Clinical Portfolio
ALISCA-Lung1 evaluates alisertib monotherapy in extensive-stage small cell lung cancer, while ALISCA-Lung2 evaluates alisertib with paclitaxel. ALISCA-Breast1 combines alisertib with endocrine therapy in chemotherapy-naive metastatic breast cancer.
Future catalysts
- Initiation of enrollment in the ALISCA-Lung2 Phase 1/2 trial in the third quarter of 2026.
- Enrollment expansion in ALISCA-Lung1 and ALISCA-Breast1 in the second half of 2026.
- Updated Phase 2 data from ALISCA-Breast1 in the fourth quarter of 2026.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Puma Biotechnology Inc (PBYI)?
Puma Biotechnology Inc (PBYI) most recently closed at 9.84 USD, a -0.91% move versus the previous session.
What is the market cap of Puma Biotechnology Inc (PBYI)?
Puma Biotechnology Inc currently has a market capitalization of 355M USD on BioPharmSignal.
What does Puma Biotechnology Inc do?
Commercial Oncology Company Puma Biotechnology develops and commercializes therapies for breast cancer and other solid tumors. Its business combines the established NERLYNX franchise with clinical development of the Aurora kinase A inhibitor alisertib. NERLYNX in HER2-Positive Breast Cancer NERLYNX, or neratinib, is an oral irreversible pan-HER kinase...
On which exchange is PBYI stock listed?
Puma Biotechnology Inc (PBYI) is associated with NASDAQ, United States, Biopharma.
What is neratinib?
NERLYNX in HER2-Positive Breast Cancer NERLYNX, or neratinib, is an oral irreversible pan-HER kinase inhibitor.
Which conditions is Puma Biotechnology Inc targeting with neratinib?
Puma Biotechnology Inc is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Puma Biotechnology Inc describe recent progress with neratinib?
Initiation of enrollment in the ALISCA-Lung2 Phase 1/2 trial in the third quarter of 2026. Enrollment expansion in ALISCA-Lung1 and ALISCA-Breast1 in the second half of 2026. Updated Phase 2 data from ALISCA-Breast1 in the fourth quarter of 2026.
What is trastuzumab?
It is approved as extended adjuvant treatment after trastuzumab-based therapy in early-stage HER2-positive breast cancer and with capecitabine in previously treated advanced or metastatic HER2-positive disease.